PWA
FDMT icon

Principia Wealth Advisory’s 4D Molecular Therapeutics FDMT Stock Holding History

Principia Wealth Advisory’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,668
Closed -$500K – 1074
2026
Q1 		$500K Hold
53,668
– – 0.28% 45
2025
Q4 		$403K Buy
+53,668
New +$544K 0.25% 52

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Principia Wealth Advisory's FDMT Position: Q2 2026 in Review

Principia Wealth Advisory sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 53,668 shares — an estimated $500K sold.

Principia Wealth Advisory first reported a position in FDMT in Q4 2025 and held it in 2 quarters. The position peaked at $500K in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Principia Wealth Advisory reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Principia Wealth Advisory sold 53,668 4D Molecular Therapeutics shares in Q2 2026, an estimated $500K.
  • Principia Wealth Advisory first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 2 quarters.
  • Principia Wealth Advisory's 4D Molecular Therapeutics position peaked at $500K in Q1 2026.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.